Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Lung cancer diagnostic intervals in England linked to heavy imaging use

National real-world data from England show long lung cancer diagnostic intervals, frequent chest imaging and high A&E use during the workup.

By Dr. Revathy Mohan V.R., MBBS · Oct 25, 2026 · 6 min read

Oncology·BMJ Open

BESPOKE IO tests ctDNA to guide immunotherapy in advanced solid tumors

BESPOKE IO will evaluate whether serial ctDNA testing can guide immunotherapy decisions in advanced solid tumors across more…

Oct 24, 2026

Oncology·BBC Dental

Throat cancer diagnosis for AFC Wimbledon assistant Terry Skiverton

AFC Wimbledon assistant Terry Skiverton has been diagnosed with throat cancer and will begin treatment in the coming…

Oct 24, 2026

Oncology·BBC Dental

Breast Cancer Nurse Chooses Full Treatment Path After Diagnosis

A Northamptonshire nurse describes breast cancer treatment, early diagnosis, and why triple-positive disease led her to choose surgery,…

Oct 24, 2026

Oncology·BBC Dental

Breast cancer: Vanessa Trump says tests came back clear after treatment

Vanessa Trump says she is cancer-free six months after a breast cancer diagnosis, with the update tied to…

Oct 24, 2026

Oncology·JNCI

Focused ultrasound could expand brain metastases treatment options

A neuro-oncology review examines how focused ultrasound may improve drug delivery, biopsy, radiosensitization, and immunotherapy for brain metastases.

Oct 24, 2026

Oncology·JCO

Liquid Biopsy Biomarkers for HPV-Associated Oral Cancer Gain Traction

Saliva and blood biomarkers may improve early detection and surveillance in HPV-associated oral and oropharyngeal cancer, but validation…

Oct 24, 2026

Oncology·ScienceDaily

Glioblastoma invasion rises in thick fluid, study finds

An open microfluidic chip shows thick tumor fluid can make glioblastoma cells smaller, more flexible, and more invasive…

Oct 24, 2026

Oncology·ACC-PRO

Lilly reports strong Sofe-M response in platinum-sensitive ovarian cancer

Lilly’s phase 1 Sofe-M data in platinum-sensitive ovarian cancer showed a 79.3% response rate and manageable safety ahead…

Oct 24, 2026

Oncology·ACC-PRO

Merck and Moderna cancer vaccine posts phase 3 melanoma win at ESMO

Merck and Moderna’s phase 3 melanoma vaccine data showed improved recurrence-free survival, though distant metastasis results were softer…

Oct 24, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.